Physician profile
Kate Zimmermann
NPI 1326623570
$975.00
in general payments reported to CMS, 2019-2025
9 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $113 · 2022: $330 · 2023: $354 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $231.90 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $125.04 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $110.29 | 2023 | Uzedy |
| Ultragenyx Pharmaceutical INC. | $105.86 | 2022 | |
| Abbvie INC. | $101.05 | 2025 | |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $98.88 | 2022 | |
| Merz North America, INC. | $83.12 | 2023-2025 | |
| Galderma Laboratories, L.P. | $17.94 | 2025 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Zimmermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.